Mylan Garners Approval of Water-Dispersible Zidovudine Tablets

Mylan's subsidiary, Matrix Laboratories, announced that under the President's Emergency Plan for AIDS Relief (PEPFAR), the FDA has approved water-dispersible zidovudine tablets, a generic version of Retrovir (GlaxoSmithKline). The water-dispersible tablet formulation allows for zidovudine to be easily administered to all patients, adults or children, who are unable to swallow tablets or capsules.

Matrix's water-dispersible zidovudine tablets will be available in a 100mg dosage strength. Zidovudine is indicated for the treatment of HIV infection and for the prevention of maternal-fetal HIV transmission.

For more information call (800) RX-MYLAN or visit www.mylan.com.